Aclaris Therapeutics (ACRS) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of Aclaris Therapeutics (NASDAQ:ACRS) from a buy rating to a hold rating in a research note issued to investors on Tuesday morning.

According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

Other equities analysts have also issued reports about the company. Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the stock a buy rating in a research report on Friday, December 21st. JMP Securities reduced their price target on Aclaris Therapeutics from $47.00 to $34.00 and set a buy rating on the stock in a research report on Tuesday, October 16th. BidaskClub raised Aclaris Therapeutics from a sell rating to a hold rating in a research report on Wednesday, January 2nd. Finally, ValuEngine lowered Aclaris Therapeutics from a hold rating to a sell rating in a research report on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $39.35.

Aclaris Therapeutics stock opened at $7.19 on Tuesday. The company has a market cap of $302.52 million, a P/E ratio of -2.88 and a beta of 1.59. Aclaris Therapeutics has a one year low of $6.15 and a one year high of $26.25.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.06) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.19. The firm had revenue of $1.63 million for the quarter, compared to analyst estimates of $1.58 million. Aclaris Therapeutics had a negative return on equity of 63.74% and a negative net margin of 1,578.24%. Analysts predict that Aclaris Therapeutics will post -4 earnings per share for the current fiscal year.

In other Aclaris Therapeutics news, Director Anand Mehra bought 372,093 shares of the business’s stock in a transaction on Monday, October 22nd. The shares were bought at an average cost of $10.75 per share, with a total value of $3,999,999.75. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 17.00% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. Morgan Stanley raised its position in shares of Aclaris Therapeutics by 481.8% during the 3rd quarter. Morgan Stanley now owns 383,818 shares of the biotechnology company’s stock valued at $5,573,000 after acquiring an additional 317,847 shares in the last quarter. MetLife Investment Advisors LLC grew its stake in Aclaris Therapeutics by 68.6% during the 3rd quarter. MetLife Investment Advisors LLC now owns 22,178 shares of the biotechnology company’s stock worth $322,000 after buying an additional 9,021 shares during the last quarter. Man Group plc grew its stake in Aclaris Therapeutics by 396.1% during the 3rd quarter. Man Group plc now owns 402,624 shares of the biotechnology company’s stock worth $5,846,000 after buying an additional 321,458 shares during the last quarter. Jefferies Group LLC bought a new position in Aclaris Therapeutics during the 3rd quarter worth $243,000. Finally, Citadel Advisors LLC grew its stake in Aclaris Therapeutics by 1.6% during the 3rd quarter. Citadel Advisors LLC now owns 882,364 shares of the biotechnology company’s stock worth $12,812,000 after buying an additional 14,134 shares during the last quarter. 72.36% of the stock is currently owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

See Also: What is the Coverage Ratio?

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply